Learning from US Mortalities in 2020

When you repeat a mistake, it is no longer a mistake: it is a decision.

– Paulo Coelho

Much has been written in the last few months about the Centers for Disease Control and Prevention (CDC) findings that life expectancy declined in the United States by a full year during the first six months of 2020. This startling number is in line with previously published findings indicating that US life expectancy would decline by 1.1 years as a result of the current pandemic, with racial and ethnic minorities facing the most severe impacts.

In our roles as healthcare providers, there is a lot to consider in these data. The findings represent a single-year decline unlike any seen since World War II in the 1940s. It is a step backward of almost 20 years in terms of public health efforts to close the life expectancy gaps that exist among US minority and socially vulnerable populations.

recent publication in JAMA provides an expanded view of the challenges brought on by the pandemic as seen in the disheartening mortality numbers from 2020 (see table below). While the leading causes of death are similar to prior years, there are significant spikes to consider as we try to learn from what we have experienced in the last year. These spikes can point toward areas where immediate intervention could be the difference between 2020 data and what 2021 data may look like.

As anticipated, mortality associated with COVID-19 constituted the lionshare of the overall increase. Alarmingly, several causes of death (compared to 2019 numbers) were associated with substantially higher numbers, including those from heart disease (4.8%), Alzheimer disease (9.8%), and diabetes (15.4%).

And while cancer-related deaths were unchanged in the 2020 data, there was a significant impact on this population as well and a measurable adverse impact on mortality may well manifest itself in coming months and years. Already in 2021, radiation oncologists report that patients are consistently arriving for care with more advanced stages of cancer than in pre-pandemic times, one sign that an impact of treatment interruptions may still be felt.

But there is an opportunity for us to ensure that these 2020 figures do not become a new trend. Rapid increases in deaths or identification of late-stage diseases are in many cases attributable to decisions made by patients to avoid or delay care until the situation has become dire. As regular check ups were skipped and signs of worsening symptoms not shared with caregivers, opportunities for healthcare providers to intervene were less available.

It might be tempting to think that as COVID-19 vaccinations increase and infections decrease, patients will be willing to return to hospitals and provider offices as before. But that return won’t begin to close the health gap for Black, Latino and other minorities and socially vulnerable populations who, these data clearly tell us, have disproportionately borne the mortality, economic, and psychological brunt of the pandemic. We must change practice to change minds and to meet patients’ changing expectations of:

Leading healthcare providers are adapting. From fast and efficient telehealth consultations to improved cardiac testing with coronary CT in both acute and outpatient settings, options are improving to deliver treatment with an increased understanding of each patient’s individual situation.

But if these innovations improve care only for those who are already getting care, then these dismaying 2020 mortality data will be our new normal. The adage that “all healthcare is local” reminds us that we can make a difference where we are now. As we learn from the past 12 months and reach out, we can arrive at a better place than where we began the journey.

And that will be a very conscious decision.

— A perspective from HeartFlow Chief Medical Officer, Campbell Rogers, MD
Bio | LinkedIn

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.